AR031930A1 - Antagonistas de mch y su uso en el tratamiento de la obesidad - Google Patents
Antagonistas de mch y su uso en el tratamiento de la obesidadInfo
- Publication number
- AR031930A1 AR031930A1 ARP010105839A ARP010105839A AR031930A1 AR 031930 A1 AR031930 A1 AR 031930A1 AR P010105839 A ARP010105839 A AR P010105839A AR P010105839 A ARP010105839 A AR P010105839A AR 031930 A1 AR031930 A1 AR 031930A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- treatment
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Se describen compuestos representados por la formula estructural (1) o una sal, éster o solvato farmacéuticamente aceptable de los mismos, en donde W es R1 ûCR3R12NR4C(O)- o R11C(O)NR4-, la línea punteada es un enlace doble opcional; X es ûCHR8-, -C(O)-, o ûC(=NOR9)-; Y es>CH-, >C(OH)- o >C(alcoxiC1-4)-; R1 es cicloalquilalquillo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterocicloalquilo, heterocicloalquil-alquilo, o cicloalquilo opcionalmente sustituido; R2 es heteroarilo o arilo opcionalmente sustituido; R3 es alquilo, arilo o heteroarilo, R4 y R12 son H o alquilo, R8 es H, alquilo o alcoxialquilo; R9 es H, alquilo o arilalquilo; R10 es H, alquilo o arilo; R11 es formula (2) o (3) o cuando R2 es R6-heteroarilo, o R10 no es H, R11 también puede ser R5-fenilalquilo; n es 1-3 y m es 1-5; y R14 es 1-3 sustituyentes seleccionados entre H, alquilo, halogeno, -OH, alcoxi y CF3; y composiciones farmacéuticas que contienen los compuestos, y métodos de uso de los compuestos en el tratamiento de los desordenes de la alimentacion y la diabetes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25787300P | 2000-12-22 | 2000-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR031930A1 true AR031930A1 (es) | 2003-10-08 |
Family
ID=22978138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010105839A AR031930A1 (es) | 2000-12-22 | 2001-12-17 | Antagonistas de mch y su uso en el tratamiento de la obesidad |
Country Status (20)
Country | Link |
---|---|
US (1) | US6472394B1 (es) |
EP (1) | EP1343761B1 (es) |
JP (2) | JP4025200B2 (es) |
KR (1) | KR20040011447A (es) |
CN (1) | CN1273451C (es) |
AR (1) | AR031930A1 (es) |
AT (1) | ATE302185T1 (es) |
AU (1) | AU2002231097B2 (es) |
CA (1) | CA2431953A1 (es) |
DE (1) | DE60112791T2 (es) |
ES (1) | ES2243588T3 (es) |
HK (1) | HK1054390B (es) |
HU (1) | HUP0302582A2 (es) |
IL (1) | IL155772A0 (es) |
MX (1) | MXPA03005744A (es) |
MY (1) | MY134017A (es) |
NZ (1) | NZ525723A (es) |
PE (1) | PE20020658A1 (es) |
WO (1) | WO2002051809A1 (es) |
ZA (1) | ZA200303638B (es) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2414198A1 (en) | 2000-07-06 | 2002-01-17 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
JP2004529161A (ja) | 2001-05-04 | 2004-09-24 | トゥラリック インコーポレイテッド | 縮合複素環式化合物 |
BR0209932A (pt) * | 2001-05-22 | 2004-10-13 | Neurogen Corp | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto |
US7084156B2 (en) | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
CA2472470A1 (en) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
CA2473236A1 (en) * | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
DE10238865A1 (de) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
AU2003285160B2 (en) * | 2002-11-06 | 2009-06-04 | Amgen Inc. | Fused heterocyclic compounds |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
AU2004209505B2 (en) * | 2003-02-10 | 2009-07-23 | Banyu Pharmaceutical Co., Ltd. | Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
WO2004072018A1 (ja) * | 2003-02-12 | 2004-08-26 | Takeda Pharmaceutical Company Limited | アミン誘導体 |
EP1653960A4 (en) * | 2003-08-13 | 2008-11-26 | Amgen Inc | MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST |
US20050256161A1 (en) * | 2003-08-13 | 2005-11-17 | Tempest Paul A | Melanin concentrating hormone receptor antagonists |
WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
US20060247239A1 (en) * | 2003-10-01 | 2006-11-02 | Hu Xiufeng E | Melanin concentrating hormone antagonists |
JP2007508303A (ja) * | 2003-10-01 | 2007-04-05 | ザ プロクター アンド ギャンブル カンパニー | メラニン凝集ホルモン拮抗物質 |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
US7253168B2 (en) | 2004-04-07 | 2007-08-07 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
US20050239791A1 (en) * | 2004-04-07 | 2005-10-27 | Hutchison Alan J | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
US7063034B2 (en) * | 2004-08-10 | 2006-06-20 | Watermark Paddlesports, Inc. | Spray skirt for watercraft |
EP1784390A2 (en) | 2004-08-13 | 2007-05-16 | Amgen Inc. | Substituted benzofused heterocycles |
US20090156474A1 (en) | 2004-11-01 | 2009-06-18 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
KR101397913B1 (ko) | 2005-05-30 | 2014-05-26 | 엠에스디 가부시키가이샤 | 신규 피페리딘 유도체 |
JP2008542365A (ja) * | 2005-05-31 | 2008-11-27 | アストラゼネカ・アクチエボラーグ | 新規なmchr1アンタゴニスト並びにmchr1媒介状態及び障害の処置のためのそれらの使用 |
WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
CA2617649A1 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
AU2006288153A1 (en) | 2005-09-07 | 2007-03-15 | Msd K.K. | Bicyclic aromatic substituted pyridone derivative |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
AU2006298852A1 (en) | 2005-09-30 | 2007-04-12 | F. Hoffmann-La Roche Ag | Indane derivatives as MCH receptor antagonists |
WO2007048027A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
US8163770B2 (en) | 2005-10-27 | 2012-04-24 | Msd. K. K. | Benzoxathiin derivative |
KR101318127B1 (ko) | 2005-11-10 | 2013-10-16 | 엠에스디 가부시키가이샤 | 아자 치환된 스피로 유도체 |
CA2635760C (en) * | 2005-12-28 | 2014-07-15 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
WO2007124045A2 (en) * | 2006-04-20 | 2007-11-01 | Ampla Pharmaceuticals, Inc. | Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
EP2072519A4 (en) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | DIARYLKETIMINDERIVAT |
JP5650404B2 (ja) | 2006-12-28 | 2015-01-07 | ライジェル ファーマシューティカルズ, インコーポレイテッド | N−置換−ヘテロシクロアルキルオキシベンズアミド化合物およびその使用方法 |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
WO2008140239A1 (en) * | 2007-05-11 | 2008-11-20 | Korea Research Institute Of Chemical Technology | Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CA2714617A1 (en) | 2008-03-06 | 2009-09-11 | Banyu Pharmaceutical Co., Ltd. | Alkylaminopyridine derivative |
CN101981025A (zh) | 2008-03-28 | 2011-02-23 | 万有制药株式会社 | 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物 |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JPWO2009154132A1 (ja) | 2008-06-19 | 2011-12-01 | Msd株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EA201170624A1 (ru) | 2008-10-30 | 2011-12-30 | Мерк Шарп Энд Домэ Корп. | Изоникотинамидные антагонисты рецепторов орексинов |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2898482A1 (en) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Antidiabetic bicyclic compounds |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
CA2913737A1 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
AU2019385644A1 (en) | 2018-11-20 | 2021-06-03 | Tes Pharma S.R.L. | Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase |
EP3924058A1 (en) | 2019-02-13 | 2021-12-22 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
US20230018413A1 (en) | 2019-08-08 | 2023-01-19 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
TW202227417A (zh) | 2020-08-18 | 2022-07-16 | 美商默沙東藥廠 | 雙環庚烷吡咯啶之食慾素受體促效劑 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
US6040318A (en) | 1997-06-25 | 2000-03-21 | Novo Nordisk A/S | Tricycle substituted with azaheterocyclic carboxylic acids |
KR20010102003A (ko) * | 1999-02-10 | 2001-11-15 | 피터 지. 스트링거 | 5-ht1f 효능제 |
WO2001009137A1 (en) | 1999-07-28 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
-
2001
- 2001-12-17 KR KR10-2003-7008345A patent/KR20040011447A/ko not_active Application Discontinuation
- 2001-12-17 IL IL15577201A patent/IL155772A0/xx unknown
- 2001-12-17 JP JP2002552906A patent/JP4025200B2/ja not_active Expired - Fee Related
- 2001-12-17 CN CNB018210066A patent/CN1273451C/zh not_active Expired - Fee Related
- 2001-12-17 ES ES01991369T patent/ES2243588T3/es not_active Expired - Lifetime
- 2001-12-17 MX MXPA03005744A patent/MXPA03005744A/es active IP Right Grant
- 2001-12-17 EP EP01991369A patent/EP1343761B1/en not_active Expired - Lifetime
- 2001-12-17 CA CA002431953A patent/CA2431953A1/en not_active Abandoned
- 2001-12-17 HU HU0302582A patent/HUP0302582A2/hu unknown
- 2001-12-17 NZ NZ525723A patent/NZ525723A/en unknown
- 2001-12-17 US US10/023,371 patent/US6472394B1/en not_active Expired - Fee Related
- 2001-12-17 AU AU2002231097A patent/AU2002231097B2/en not_active Ceased
- 2001-12-17 AT AT01991369T patent/ATE302185T1/de not_active IP Right Cessation
- 2001-12-17 DE DE60112791T patent/DE60112791T2/de not_active Expired - Lifetime
- 2001-12-17 AR ARP010105839A patent/AR031930A1/es unknown
- 2001-12-17 WO PCT/US2001/049301 patent/WO2002051809A1/en active IP Right Grant
- 2001-12-18 PE PE2001001268A patent/PE20020658A1/es not_active Application Discontinuation
- 2001-12-19 MY MYPI20015748A patent/MY134017A/en unknown
-
2003
- 2003-05-12 ZA ZA200303638A patent/ZA200303638B/en unknown
- 2003-09-18 HK HK03106690.7A patent/HK1054390B/zh unknown
-
2007
- 2007-07-26 JP JP2007195250A patent/JP2007284451A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2002051809A1 (en) | 2002-07-04 |
US6472394B1 (en) | 2002-10-29 |
EP1343761B1 (en) | 2005-08-17 |
MY134017A (en) | 2007-11-30 |
HUP0302582A2 (hu) | 2003-12-29 |
PE20020658A1 (es) | 2002-07-23 |
DE60112791D1 (de) | 2005-09-22 |
HK1054390A1 (en) | 2003-11-28 |
EP1343761A1 (en) | 2003-09-17 |
ATE302185T1 (de) | 2005-09-15 |
AU2002231097B2 (en) | 2004-12-09 |
CN1481361A (zh) | 2004-03-10 |
ZA200303638B (en) | 2004-08-12 |
HK1054390B (zh) | 2006-01-06 |
MXPA03005744A (es) | 2003-09-05 |
DE60112791T2 (de) | 2006-06-08 |
CN1273451C (zh) | 2006-09-06 |
IL155772A0 (en) | 2003-12-23 |
CA2431953A1 (en) | 2002-07-04 |
JP2004516314A (ja) | 2004-06-03 |
KR20040011447A (ko) | 2004-02-05 |
ES2243588T3 (es) | 2005-12-01 |
NZ525723A (en) | 2004-11-26 |
JP4025200B2 (ja) | 2007-12-19 |
JP2007284451A (ja) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR031930A1 (es) | Antagonistas de mch y su uso en el tratamiento de la obesidad | |
BR9305182A (pt) | Composto e formulação farmaceûtica | |
AR033306A1 (es) | Compuestos | |
AR047557A1 (es) | Compuestos derivados de piridazina y su uso como agentes terapeuticos | |
EE200900004A (et) | Dopamiini neurotransmissiooni modulaatorid, nende kasutamine ja neid hendeid sisaldavad farmatseutilised kompositsioonid | |
NO20085077L (no) | Nye forbindelser | |
ES2187983T3 (es) | Derivados 1,2,3,4-tetrahidronaftaleno sustituidos. | |
NO20062098L (no) | Faststofftilstandmontelukast | |
HRP20080052T3 (en) | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation | |
AR015449A1 (es) | Derivados piperidil- o peperazinil-dihidro sustituidos-2h-1-benzopirano composicion farmaceutica que los contiene, su uso para la elaboracion de unmedicamento, procedimiento para su preparacion y compuesto intermediario para su exclusivo uso en dicho procedimiento | |
KR950000663A (ko) | 트리테르펜 유도체 및 이를 함유하는 엔도텔린-수용체 길항물질 | |
NO20051958L (no) | Forbindelser | |
ECSP045096A (es) | Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1" | |
CA2104456A1 (en) | Pyridine- and Imidazole-Derived Agents for Cardiovascular Diseases | |
FI913034A0 (fi) | Foerening med magsyrainhiberande effekt och foerfarande foer dess framstaellning. | |
PE20040668A1 (es) | Nuevos derivados de piperidina | |
ATE28862T1 (de) | Aktive kompositionen gegen motten, weisse fliegen und holzwuermer, pharmazeutische kompositionen und benzoylharnstoffderivaten. | |
ATE406363T1 (de) | Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten | |
KR950700293A (ko) | 세로토닌작동성의 에르골린 유도체(Serotoninergic ergoline derivatives) | |
AR029374A1 (es) | Compuestos derivados de benceno, su utilizacion, un procedimiento para su preparacion y una composicion farmaceutica que los contiene | |
NO913023D0 (no) | Nye bicykliske aminosubstituerte forbindelsr. | |
DK0556813T3 (da) | Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler | |
ATE170851T1 (de) | Guanidinothiazolederivate und ihre anwendung als h2-rezeptor-antagonisten | |
BR0112957A (pt) | Composto, método de tratamento, uso de um composto, e, composição farmacêutica | |
NO950177L (no) | Farmakologisk aktive erivater |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |